Stockscreener 앱 받기
17.97
0.45%
0.08
시장 영업 전:
18.10
0.13
+0.72%
전일 마감가:
$17.89
열려 있는:
$17.89
하루 거래량:
2.33M
Relative Volume:
0.85
시가총액:
$2.30B
수익:
$1.00B
순이익/손실:
$22.39M
주가수익비율:
145.51
EPS:
0.1235
순현금흐름:
$45.01M
1주 성능:
-2.28%
1개월 성능:
-21.18%
6개월 성능:
-21.90%
1년 성능:
-27.57%
1일 변동 폭
$17.57
$18.01
1주일 범위
$17.43
$19.36
52주 변동 폭
$16.10
$30.48
아펠리스 Stock (APLS) Company Profile
명칭
Apellis Pharmaceuticals Inc
전화
617-977-5700
주소
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
17.97 | 2.30B | 1.00B | 22.39M | 45.01M | 0.1235 |
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 116.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 77.96B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
684.50 | 42.36B | 4.16B | 1.29B | 734.26M | 19.59 |
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
아펠리스 Stock (APLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-13 | 개시 | Roth Capital | Buy |
| 2026-01-28 | 개시 | Barclays | Equal Weight |
| 2026-01-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-11-06 | 개시 | Wolfe Research | Peer Perform |
| 2025-10-15 | 개시 | Wells Fargo | Overweight |
| 2025-09-26 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-05-09 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-05-09 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-17 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-11-21 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-10-25 | 개시 | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-16 | 개시 | William Blair | Outperform |
| 2024-05-31 | 개시 | Piper Sandler | Neutral |
| 2024-02-05 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-12-14 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | 개시 | Goldman | Buy |
| 2023-11-02 | 개시 | Mizuho | Neutral |
| 2023-10-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-09-15 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | 재확인 | Citigroup | Buy |
| 2023-08-03 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-08-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-01-03 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-19 | 개시 | H.C. Wainwright | Buy |
| 2022-06-17 | 재개 | Stifel | Buy |
| 2022-04-14 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-29 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-09-10 | 재확인 | BMO Capital Markets | Outperform |
| 2021-09-10 | 재확인 | Credit Suisse | Neutral |
| 2021-09-10 | 재확인 | Needham | Buy |
| 2021-09-10 | 재확인 | Oppenheimer | Outperform |
| 2021-09-10 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-08-19 | 개시 | Jefferies | Buy |
| 2021-08-19 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-16 | 개시 | Goldman | Buy |
| 2020-11-19 | 개시 | Needham | Buy |
| 2020-09-01 | 개시 | Stifel | Buy |
| 2020-07-20 | 개시 | ROTH Capital | Buy |
| 2020-06-17 | 개시 | BTIG Research | Neutral |
| 2020-04-01 | 개시 | Raymond James | Strong Buy |
| 2020-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-11 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2020-01-07 | 개시 | SVB Leerink | Mkt Perform |
| 2019-12-19 | 개시 | BofA/Merrill | Buy |
| 2019-11-22 | 개시 | Wedbush | Underperform |
| 2019-11-05 | 개시 | Credit Suisse | Neutral |
| 2019-08-01 | 재확인 | Cantor Fitzgerald | Overweight |
| 2019-07-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-03-29 | 개시 | Robert W. Baird | Outperform |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-07-30 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-04-12 | 다운그레이드 | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
아펠리스 주식(APLS)의 최신 뉴스
Complement 3 Glomerulopathy Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | NovelMed Therapeutics, Apellis Pharma, Novartis, Amyndas Pharma - Barchart.com
Apellis Pharmaceuticals, Inc. (APLS) surpasses Q4 earnings and revenue estimates - MSN
APLS: Cantor Fitzgerald Lowers Price Target While Maintaining Ov - GuruFocus
Apellis wins new buy at Roth on Syfovre prospects - MSN
Cantor Fitzgerald Has Lowered Expectations for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - MarketBeat
Price-Driven Insight from (APLS) for Rule-Based Strategy - Stock Traders Daily
Bank of Nova Scotia Acquires 861,413 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Does Apellis Pharmaceuticals' (APLS) New Board Member Reveal a Deeper R&D Commercialization Strategy Shift? - simplywall.st
Apellis Pharmaceuticals, Inc. $APLS Shares Bought by HighVista Strategies LLC - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Assessing Apellis Pharmaceuticals (APLS) Valuation After Weaker Returns And EMPAVELI Label Expansion - Yahoo Finance
Integral Health Asset Management LLC Purchases Shares of 250,000 Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals (APLS) Receives Buy Rating Amid Growth P - GuruFocus
Analysts’ Top Healthcare Picks: Apellis Pharmaceuticals (APLS), Argenx Se (ARGX) - The Globe and Mail
Apellis (NASDAQ: APLS) CEO gifts 129,738 shares via family trusts - Stock Titan
Apellis Pharmaceuticals, Inc.Common Stock (NQ: APLS - The Chronicle-Journal
APLS: Roth Capital Initiates Coverage with 'Buy' Rating at $31.0 - GuruFocus
Apellis stock wins new Buy at Roth on Syfovre (APLS:NASDAQ) - Seeking Alpha
Apellis Pharmaceuticals (NASDAQ:APLS) Coverage Initiated at Roth Mkm - MarketBeat
Roth Capital initiates coverage of Apellis Pharmaceuticals (APLS) with buy recommendation - MSN
Here is Why JPMorgan is Overweight on Apellis Pharma (APLS) - Finviz
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds - Insider Monkey
How Apellis Adding Ex-Pfizer R&D Chief Mikael Dolsten to Its Board Will Impact Apellis (APLS) Investors - simplywall.st
Rhenman & Partners Asset Management AB Has $5.26 Million Stock Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals Balances Growth With Revenue Headwinds - The Globe and Mail
Apellis Sells Aspaveli Ex-US Royalties to Sobi for Up to $300M - MSN
Apellis Adds Ex Pfizer R&D Chief To Board As Growth Plans Evolve - Sahm
Analysts Are Bullish on These Healthcare Stocks: Veeva Systems (VEEV), Apellis Pharmaceuticals (APLS) - The Globe and Mail
(APLS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
JP Morgan Raises Price Target for APLS, Maintains Overweight Rat - GuruFocus
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $37.00 at JPMorgan Chase & Co. - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $20.00 at Mizuho - MarketBeat
APLS: Mizuho Maintains Rating, Raises Price Target | APLS Stock News - GuruFocus
Assessing Apellis Pharmaceuticals: Insights From 11 Financial Analysts - Benzinga
APLS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Update Recap: Will Apellis Pharmaceuticals Inc benefit from geopolitical trendsMarket Performance Summary & Daily Technical Forecast Reports - baoquankhu1.vn
Apellis Pharmaceuticals (APLS) director receives new stock options and RSUs - Stock Titan
Apellis (APLS) director Mikael Dolsten submits initial Form 3 insider filing - Stock Titan
Apellis Pharmaceuticals (APLS) Stock Analysis: Exploring a 62.73% Upside Potential in Biotech - DirectorsTalk Interviews
Apellis Pharmaceuticals Details SYFOVRE, EMPAVELI Growth Plans and FcRn Gene-Editing Push at TD Cowen Conf. - MarketBeat
Analysts Offer Insights on Healthcare Companies: Arcellx Inc (ACLX) and Apellis Pharmaceuticals (APLS) - The Globe and Mail
Apellis adds former Pfizer research chief to board - Investing.com
Apellis Pharmaceuticals appoints Mikael Dolsten to board of directors - Investing.com Australia
Apellis Pharmaceuticals2026 Funding Rounds & List of Investors - Tracxn
Apellis Pharmaceuticals, Inc. $APLS Shares Sold by Vanguard Group Inc. - MarketBeat
Apellis Pharmaceuticals Adds Mikael Dolsten to Board - TipRanks
Apellis Pharmaceuticals appoints Mikael Dolsten to board of directors By Investing.com - Investing.com India
Apellis adds former Pfizer research chief to board By Investing.com - Investing.com Canada
Apellis Appoints Mikael Dolsten, M.D., Ph.D., To Board - citybiz
Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors - Bitget
Mikael Dolsten joins Apellis Board as Class I director - TradingView
아펠리스 (APLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):